Key result
This study protocol outlines a planned prospective observational study of 1,000 patients to evaluate an accelerated chest pain pathway using point-of-care troponin in rural New Zealand.
Why the study?
Accelerated chest pain pathways rely on lab-based troponin assays not widely available in rural settings, and larger studies are needed to confirm the safety of an adapted pathway using point-of-care troponin.
Does an accelerated chest pain pathway using point-of-care troponin safely identify low-risk patients for early discharge in rural settings?
Observational (n=1,000)
Yes
Does an accelerated chest pain pathway using point-of-care troponin safely identify low-risk patients for early discharge in rural settings?
This study protocol outlines a prospective observational study to evaluate the safety and effectiveness of an accelerated chest pain pathway using point-of-care troponin in rural New Zealand.
Prospective rural chest pain pathway data pending; leaves open whether point-of-care troponin safely enables early discharge.
INTRODUCTION Accelerated diagnostic chest pain pathways are used widely in urban New Zealand hospitals. These pathways use laboratory-based troponin assays with good analytical precision. Widespread implementation has not occurred in many of New Zealand's rural hospitals and general practices as they are reliant on point-of-care troponin assays, which are less sensitive and precise. An accelerated chest pain pathway using point-of-care troponin has been adapted for use in rural settings. A pilot study in a low-risk rural population showed no major adverse cardiac events at 30 days. A larger study is required to be confident that the pathway is safe. AIMS To assess the safety and effectiveness of an accelerated chest pain pathway adapted for rural settings and general practice using point-of-care troponin to identify low-risk patients and allow early discharge. METHODS This is a prospective observational study of an accelerated chest pain pathway using point-of-care troponin in rural hospitals and general practices in New Zealand. A total of 1000 patients, of whom we estimate 400 will be low risk, will be enrolled in the study. OUTCOME MEASURES The primary outcome is the proportion of patients identified by the pathway as low risk for a 30-day major adverse cardiac event. Secondary outcomes include the proportion of low-risk patients who were discharged directly from general practice or rural hospitals, the proportion of patients reclassified as having acute myocardial infarction by the pathway and the proportion of patients with low and intermediate risk safely managed in the rural hospital.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2020) conducted an observational in Chest pain (n=1,000). Accelerated chest pain pathway using point-of-care troponin was evaluated on Proportion of patients identified by the pathway as low risk for a 30-day major adverse cardiac event. This study protocol outlines a planned prospective observational study of 1,000 patients to evaluate an accelerated chest pain pathway using point-of-care troponin in rural New Zealand.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: